For example, using neuroblastoma cells, Decaesteker et al. (2018) reported 557 TBX2 binding sites (q < 0.05) in total (41% intergenic; 30% lincRNAs; binding to consensus AGGTGTGA), while a more recent study of embryonic lungs (Lüdtke et al. 2021) identified a total of 3062 Tbx2 peaks enriched >3.5-fold over the control, but only 177 were found within 5 kb of transcription start sites (TSSs), and in neither study were replicates used to robustly identify target sites. The gene discussed is TBX2; the disease is neuroblastoma.